• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Avantor Inc.

    3/28/25 4:19:04 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    DEFA14A 1 avtr-na_2025.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant under §240.14a-12

    AVANTOR, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

     

    img198531507_0.jpg

     

    Your Vote Counts! AVANTOR, INC. 2025 Annual Meeting Vote by May 7, 2025 11:59 PM ET AVANTOR, INC. RANDOR CORPORATE CENTER BUILDING ONE, SUITE 200 100 MATSONFORD ROAD RADNOR, PA 19087 V65550-P26497 You invested in AVANTOR, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 8, 2025. Get informed before you vote View the Notice & Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 24, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 8, 2025 11:00 AM ET Virtually at: www.virtualshareholdermeeting.com/AVTR2025*Please check the meeting materials for any special requirements for meeting attendance. V2.0

     

     


     

     

    img198531507_1.jpg

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials at www.proxyvote.com or request a paper or email copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. Election of Directors Nominees: 1a. Juan Andres 1b. John Carethers 1c. Lan Kang 1d. Dame Louise Makin 1e. Joseph Massaro 1f. Mala Murthy 1g. Jonathan Peacock 1h. Michael Severino 1i. Michael Stubblefield 1j. Gregory Summe 2. Ratification of the Appointment of Deloitte & Touche LLP as the Company’s independent registered accounting firm for 2025. 3. Approve, on an Advisory Basis, Named Executive Officer Compensation. NOTE: To consider such other business as may properly come before the meeting or any adjournment or postponement thereof. Board Recommends For For For For For For For For For For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V65551-P26497

     

     


    Get the next $AVTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/9/25 4:51:58 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Massaro Joseph R bought $99,630 worth of shares (8,100 units at $12.30), increasing direct ownership by 30% to 35,038 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      4/29/25 5:58:52 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $312,500 worth of shares (25,000 units at $12.50) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      4/29/25 5:58:40 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

      RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time.  To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience

      5/2/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Announces CEO Transition

      Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

      4/25/25 6:07:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Reports First Quarter 2025 Results

      Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

      4/25/25 6:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      11/14/24 1:28:33 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      8/9/24 3:22:24 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      8/7/24 4:09:12 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

      RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

      11/6/24 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

      NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS

      7/23/24 7:17:00 PM ET
      $APO
      $AVTR
      $HIBB
      $QDEL
      Investment Managers
      Finance
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avantor downgraded by Goldman with a new price target

      Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

      4/29/25 8:05:35 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by TD Cowen with a new price target

      TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

      4/28/25 8:32:10 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by Stifel with a new price target

      Stifel downgraded Avantor from Buy to Hold and set a new price target of $14.00

      4/28/25 8:31:49 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Financials

    Live finance-specific insights

    See more
    • Avantor® Announces CEO Transition

      Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

      4/25/25 6:07:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Reports First Quarter 2025 Results

      Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

      4/25/25 6:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Report First Quarter 2025 Earnings on Friday, April 25, 2025

      RADNOR, Pa., March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

      3/28/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Laboratory Solutions Walker Corey was granted 162,866 shares, increasing direct ownership by 229% to 234,001 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:49 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Carethers John was granted 17,100 shares, increasing direct ownership by 59% to 45,858 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:39 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP & Chief Accounting Officer Eck Steven W was granted 20,358 shares, increasing direct ownership by 51% to 59,929 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:27 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    SEC Filings

    See more
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      5/12/25 5:16:45 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      4/28/25 8:29:56 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Avantor Inc.

      10-Q - Avantor, Inc. (0001722482) (Filer)

      4/25/25 9:00:12 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials